Opinion|Videos|October 21, 2024
Health Care Resource Utilization: Luspatercept vs ESAs in MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).
Advertisement
Episodes in this series
Video content above is prompted by the following:
Health care resource utilization is an important factor in deciding on treatments and affects quality of life for patients.
- Please briefly discuss the real-world data presented at SOHO comparing the health resource utilization of US patients with MDS treated with luspatercept vs ESAs.
Advertisement
Related to this article
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Durability of PFS and OS Benefit vs. Historical Control
5